Charles River Laboratories International, Inc.

No forensic scores are on file for this company, so this synthesis does not describe a Beneish M-Score, Piotroski F-Score, Altman Z-Score, or Fog Index result. The risk-factor text, legal proceedings, debt instruments, and segment descriptions are also absent, which means specific programs or matters cannot be named here. The annual financial facts tell a clear story of scale followed by compression. Revenue rose from $2.27 billion in 2018-FY to $4.13 billion in 2023-FY, then eased to $4.02 billion in 2025-FY. Operating income climbed from $331.38 million in 2018-FY to $650.98 million in 2022-FY, then declined to $617.26 million in 2023-FY, $227.35 million in 2024-FY, and $25.16 million in 2025-FY. Net income was $22.2 million in 2024-FY and a loss of $144.34 million in 2025-FY, a swing of about $166.5 million in one year. Because the net loss is far larger than the operating result, the difference must come from non-operating or tax items, but their nature is not in the data supplied and is not inferred here. A careful reader would want to see the MD&A explanation of the margin decline, the risk-factor disclosures about the company's operating environment, and the cash flow and balance sheet detail before drawing conclusions about durability. Forensic screens would also add a structured check on reported earnings quality, and those are not available for this filing. The verifiable conclusion from the data on hand is narrow: revenue has been broadly stable recently, while profitability has fallen sharply and turned negative at the net level in 2025-FY. The reasons behind that shift require the filing narrative that is missing from this dataset.

Catalyst.The filings supplied for this synthesis do not include MD&A text, so this section cannot attribute any driver to management. The reported annual figures show revenue of $4.02 billion for 2025-FY, compared with $4.05 billion for 2024-FY, a decline of about 0.7%. Revenue was $4.13 billion in 2023-FY and $2.27 billion in 2018-FY, so the top line has grown over the longer period but has been roughly flat since 2023. What is driving the business right now cannot be determined from the data on file. Readers may want to look at the MD&A section of the company's annual report directly.

Hidden risk.The most visible tension in the numbers is the gap between revenue and profit. Operating income fell from $227.35 million in 2024-FY to $25.16 million in 2025-FY, a decline of about 89%, while revenue moved less than 1%. Operating margin, computed from these figures, was about 5.6% in 2024-FY and about 0.6% in 2025-FY, down from about 14.9% in 2023-FY. The company also reported a net loss of $144.34 million for 2025-FY, compared with net income of $22.2 million the prior year. The filing text that would explain these movements is not on file, so the cause cannot be identified here.